Cargando…
Genome-Based Drug Target Identification in Human Pathogen Streptococcus gallolyticus
Streptococcus gallolysticus (Sg) is an opportunistic Gram-positive, non-motile bacterium, which causes infective endocarditis, an inflammation of the inner lining of the heart. As Sg has acquired resistance with the available antibiotics, therefore, there is a dire need to find new therapeutic targe...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027347/ https://www.ncbi.nlm.nih.gov/pubmed/33841489 http://dx.doi.org/10.3389/fgene.2021.564056 |
_version_ | 1783675799316987904 |
---|---|
author | Qureshi, Nosheen Afzal Bakhtiar, Syeda Marriam Faheem, Muhammad Shah, Mohibullah Bari, Ahmed Mahmood, Hafiz M. Sohaib, Muhammad Mothana, Ramzi A. Ullah, Riaz Jamal, Syed Babar |
author_facet | Qureshi, Nosheen Afzal Bakhtiar, Syeda Marriam Faheem, Muhammad Shah, Mohibullah Bari, Ahmed Mahmood, Hafiz M. Sohaib, Muhammad Mothana, Ramzi A. Ullah, Riaz Jamal, Syed Babar |
author_sort | Qureshi, Nosheen Afzal |
collection | PubMed |
description | Streptococcus gallolysticus (Sg) is an opportunistic Gram-positive, non-motile bacterium, which causes infective endocarditis, an inflammation of the inner lining of the heart. As Sg has acquired resistance with the available antibiotics, therefore, there is a dire need to find new therapeutic targets and potent drugs to prevent and treat this disease. In the current study, an in silico approach is utilized to link genomic data of Sg species with its proteome to identify putative therapeutic targets. A total of 1,138 core proteins have been identified using pan genomic approach. Further, using subtractive proteomic analysis, a set of 18 proteins, essential for bacteria and non-homologous to host (human), is identified. Out of these 18 proteins, 12 cytoplasmic proteins were selected as potential drug targets. These selected proteins were subjected to molecular docking against drug-like compounds retrieved from ZINC database. Furthermore, the top docked compounds with lower binding energy were identified. In this work, we have identified novel drug and vaccine targets against Sg, of which some have already been reported and validated in other species. Owing to the experimental validation, we believe our methodology and result are significant contribution for drug/vaccine target identification against Sg-caused infective endocarditis. |
format | Online Article Text |
id | pubmed-8027347 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80273472021-04-09 Genome-Based Drug Target Identification in Human Pathogen Streptococcus gallolyticus Qureshi, Nosheen Afzal Bakhtiar, Syeda Marriam Faheem, Muhammad Shah, Mohibullah Bari, Ahmed Mahmood, Hafiz M. Sohaib, Muhammad Mothana, Ramzi A. Ullah, Riaz Jamal, Syed Babar Front Genet Genetics Streptococcus gallolysticus (Sg) is an opportunistic Gram-positive, non-motile bacterium, which causes infective endocarditis, an inflammation of the inner lining of the heart. As Sg has acquired resistance with the available antibiotics, therefore, there is a dire need to find new therapeutic targets and potent drugs to prevent and treat this disease. In the current study, an in silico approach is utilized to link genomic data of Sg species with its proteome to identify putative therapeutic targets. A total of 1,138 core proteins have been identified using pan genomic approach. Further, using subtractive proteomic analysis, a set of 18 proteins, essential for bacteria and non-homologous to host (human), is identified. Out of these 18 proteins, 12 cytoplasmic proteins were selected as potential drug targets. These selected proteins were subjected to molecular docking against drug-like compounds retrieved from ZINC database. Furthermore, the top docked compounds with lower binding energy were identified. In this work, we have identified novel drug and vaccine targets against Sg, of which some have already been reported and validated in other species. Owing to the experimental validation, we believe our methodology and result are significant contribution for drug/vaccine target identification against Sg-caused infective endocarditis. Frontiers Media S.A. 2021-03-25 /pmc/articles/PMC8027347/ /pubmed/33841489 http://dx.doi.org/10.3389/fgene.2021.564056 Text en Copyright © 2021 Qureshi, Bakhtiar, Faheem, Shah, Bari, Mahmood, Sohaib, Mothana, Ullah and Jamal. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Qureshi, Nosheen Afzal Bakhtiar, Syeda Marriam Faheem, Muhammad Shah, Mohibullah Bari, Ahmed Mahmood, Hafiz M. Sohaib, Muhammad Mothana, Ramzi A. Ullah, Riaz Jamal, Syed Babar Genome-Based Drug Target Identification in Human Pathogen Streptococcus gallolyticus |
title | Genome-Based Drug Target Identification in Human Pathogen Streptococcus gallolyticus |
title_full | Genome-Based Drug Target Identification in Human Pathogen Streptococcus gallolyticus |
title_fullStr | Genome-Based Drug Target Identification in Human Pathogen Streptococcus gallolyticus |
title_full_unstemmed | Genome-Based Drug Target Identification in Human Pathogen Streptococcus gallolyticus |
title_short | Genome-Based Drug Target Identification in Human Pathogen Streptococcus gallolyticus |
title_sort | genome-based drug target identification in human pathogen streptococcus gallolyticus |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027347/ https://www.ncbi.nlm.nih.gov/pubmed/33841489 http://dx.doi.org/10.3389/fgene.2021.564056 |
work_keys_str_mv | AT qureshinosheenafzal genomebaseddrugtargetidentificationinhumanpathogenstreptococcusgallolyticus AT bakhtiarsyedamarriam genomebaseddrugtargetidentificationinhumanpathogenstreptococcusgallolyticus AT faheemmuhammad genomebaseddrugtargetidentificationinhumanpathogenstreptococcusgallolyticus AT shahmohibullah genomebaseddrugtargetidentificationinhumanpathogenstreptococcusgallolyticus AT bariahmed genomebaseddrugtargetidentificationinhumanpathogenstreptococcusgallolyticus AT mahmoodhafizm genomebaseddrugtargetidentificationinhumanpathogenstreptococcusgallolyticus AT sohaibmuhammad genomebaseddrugtargetidentificationinhumanpathogenstreptococcusgallolyticus AT mothanaramzia genomebaseddrugtargetidentificationinhumanpathogenstreptococcusgallolyticus AT ullahriaz genomebaseddrugtargetidentificationinhumanpathogenstreptococcusgallolyticus AT jamalsyedbabar genomebaseddrugtargetidentificationinhumanpathogenstreptococcusgallolyticus |